Insider Sell: BioMarin Pharmaceutical
1:32PM ET 5/04/2022 MT NewswiresGeorge Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
Quotes Snapshot > BMRN
Biomarin Pharmaceutical Inc BMRN:NASDAQ
Last Price$78.81Cboe Real-Time Last Sale as of 11:49AM ET 5/18/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.31(0.39%)
Bid (Size)$78.68 (33)
Ask (Size)$78.94 (100)
Day Low / High$77.65 - 79.99
Volume333.0 K
Read more news Recent News
Insider Sell: BioMarin Pharmaceutical
1:30PM ET 5/04/2022 MT NewswiresRichard A Meier, Director, on May 02, 2022, sold 3,878 shares in BioMarin Pharmaceutical (BMRN) for $318,345. Following the Form 4 filing with the SEC,...
Insider Sell: BioMarin Pharmaceutical
9:53AM ET 5/03/2022 MT NewswiresJean Jacques Bienaime, Director, Chief Executive Officer, on April 28, 2022, sold 25,000 shares in BioMarin Pharmaceutical (BMRN) for $2,085,550. Following...
--Oppenheimer Adjusts BioMarin Pharmaceutical Price Target to $94 From $95, Maintains Perform Rating
11:22AM ET 4/28/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
BioMarin: A Good Anchor For Your Biotech Portfolio
1:13PM ET 5/10/2022 Seeking Alphabluebird bio: Beaten Down Biotech With Possible Long-Term Potential
1:59PM ET 5/09/2022 Seeking AlphaBBH ETF: Buy This ETF At Discounted Price And Hold It For Long Term
3:34PM ET 4/28/2022 Seeking AlphaBioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2022 Results - Earnings Call Transcript
10:06PM ET 4/27/2022 Seeking AlphaCompany Profile
Business DescriptionBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA. View company web site for more details
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Recent SEC Filing | 05/11/2022 3 |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive VP-Finance | Brian R. Mueller |
| Chief Information Officer | Eduardo E. von Pervieux |
| President-Worldwide Research & Development | Henry J. Fuchs |
Company Highlights
| Price Open | $78.30 |
| Previous Close | $79.12 |
| 52 Week Range | $71.59 - 94.20 |
| Market Capitalization | $14.6 B |
| Shares Outstanding | 185.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/27/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 431.83 |
| Earnings per Share | $0.21 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | 2.10% |
| Return on Equity | 0.92% |
Analyst Ratings as of 04/25/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |